Advanced Non-Small Cell Lung Cancer Clinical Trial
Official title:
Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer Through Gene Expression Profiling.
Patients who are at least 18 years of age and have a type of cancer known as advanced
non-small cell lung cancer may be eligible for this study if they meet all of the
inclusion/exclusion criteria.
Background: The standard treatment for patients with advanced non-small cell cancer is
chemotherapy. The two drug combination, carboplatin (Paraplatin) and paclitaxel (Taxol), is
commonly used as the first treatment. Unfortunately, standard treatment with chemotherapy
only shrinks the cancer in about 30% of patients that receive it. There is no way to predict
who will or won't benefit from this treatment. The researchers at the University of Michigan
would like to determine if the genes of the lung cancers in patients enrolled in this study
will help predict whether or not the tumors shrink when exposed to standard chemotherapy.
The goal is to find a set of lung cancer genes that will predict successful treatment with
carboplatin and paclitaxel in patients with non-small cell lung cancer.
The actual treatment, carboplatin and paclitaxel, involved in this study is not
experimental. The experimental aspect of this study is the identification of predictors of
response to treatment. To do this, it would require a sample of your cancer. If your initial
surgery or biopsy was done at the University of Michigan, we may already have an adequate
sample of your cancer that could be used for this research. In that case, we are asking for
your permission to use this sample for this study. However, if you meet all eligibility
criteria and agree to participate in this research study and an adequate sample is not
available, you will need to undergo another biopsy procedure for us to obtain a sample of
your cancer. Obtaining a tumor sample is the most crucial part of this research study.
Prior to the start of treatment, subjects will have a complete history and physical
examination and blood tests to evaluate their overall health. The doctor will also obtain a
tissue sample (biopsy) of the tumor taken from the subject's body to evaluate the genes that
are expressed within the tumor. Doctors from the University of Michigan will do an analysis
on the tissue to understand the genetic nature of each subject's tumor. If the subject's
initial surgery or biopsy was done at the University of Michigan, we may already have an
adequate sample of their cancer that could be used for this research. In that case, we would
be asking for their permission to use this sample for this study. However, if subjects agree
to participate in this research study and an adequate sample is not available, they will
need to undergo another biopsy procedure for us to obtain a sample of your cancer.
A biopsy of a subject's tumor can be obtained from various sites of their body using a
number of different methods. We will select a location that will be the easiest and safest
place to biopsy, and that will provide an adequate sample of tumor tissue. Biopsy sites will
generally be superficial (for example, lymph nodes, skin nodules, chest wall tumors). The
usual method of biopsy will be the placement of a large needle into the tumor to obtain a
"core" of tissue. In some situations, we may ask to have a superficial tumor removed in
whole or part by a minor surgical procedure. If neither of these methods can be done safely,
we may place a thin needle into the tumor and aspirate (suck out) some tumor cells for
study. All procedures will be done with local anesthesia (that is, injection of medication
directly into the biopsy site to numb the area prior to biopsy) and appropriate care to
avoid excessive bleeding or subsequent infection. The doctors will explain the specific
biopsy location and technique that fits each subject's situation to them in detail prior to
the procedure. They can decide not to go through with the biopsy and withdraw from this
research trial at any time.
Subjects will then be given carboplatin and paclitaxel intravenously (through a vein) over 2
hours. This will be repeated every three weeks for a total of six to eighteen weeks. Three
weeks is considered a "cycle" and each subject will receive 1 to 6 cycles depending on how
their tumor responds and how the treatment is tolerated. Treatment will be stopped if the
tumor gets worse or if a subject develops unacceptable side-effects.
Physical examinations, blood tests, and x-rays and/or scans will be done routinely during
the therapy so the doctor can check the subject's body and your tumor response to treatment.
Blood samples, consisting of 2-3 teaspoonfuls (10-15 cc) each, will be obtained twice every
three weeks during the study to evaluate the effect of the treatment on their blood counts,
blood electrolytes, liver and kidney function.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04263051 -
Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05489731 -
VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01240447 -
Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients
|
Phase 2 | |
Completed |
NCT00737867 -
Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer
|
Phase 3 | |
Recruiting |
NCT05504278 -
Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
|
Phase 1 | |
Recruiting |
NCT05482568 -
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06043973 -
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
|
Phase 3 | |
Completed |
NCT00948675 -
Study of Participants With Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03681483 -
RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer
|
Phase 1 | |
Terminated |
NCT05001724 -
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
|
Phase 2/Phase 3 | |
Recruiting |
NCT05099172 -
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
|
Phase 1/Phase 2 | |
Recruiting |
NCT02133196 -
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT00874328 -
A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Completed |
NCT00487669 -
Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Active, not recruiting |
NCT03516981 -
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
|
Phase 2 | |
Recruiting |
NCT03334864 -
Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)
|
||
Terminated |
NCT00783471 -
Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT00330746 -
CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer
|
Phase 2 | |
Completed |
NCT03117335 -
Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
|
Phase 3 | |
Terminated |
NCT00345059 -
The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer
|
Phase 3 |